Liver X Receptor

亜型選択性的な製品

Liver X Receptor製品

• All (16)
• Liver X Receptor活性剤(1)
• Liver X Receptor拮抗剤(1)
• Liver X Receptor作動薬(7)
• 新製品

製品コード	製品名称	製品説明	文献中Selleckの製品使用例	お客様のフィードバック
S2630	GW3965 HCl	GW3965 HCl is a potent, selective LXR agonist for hLXRα and hLXRβ with EC50 of 190 and 30 nM in cell-free assays, respectively.	Int J Chron Obstruct Pulmon Dis, 2025, 20:411-423 Sci Rep, 2024, 14(1):30786 Regen Ther, 2024, 25:229-237
S7076	T0901317	T0901317 is a potent and selective agonist for both LXR and FXR, with EC50 of ~50 nM and 5 μM, respectively. T0901317 is a dual inverse agonist of RORα and RORγ with Ki of 132 nM and 51 nM, respectively. T0901317 significantly suppresses cell proliferation and induces apoptosis.	J Exp Med, 2025, 222(3)e20230647 Exp Ther Med, 2025, 29(3):46 J Anim Sci Biotechnol, 2024, 15(1):124
S8390	LXR-623	LXR-623 is a novel liver X-receptor(LXR) agonist with IC50 values of 179 nM and 24 nM for LXR-α and LXR-β, respectively. It is orally bioavailable and readily passes the blood-brain barrier.	Acta Neuropathol Commun, 2022, 10(1):40 Cancers (Basel), 2022, 14(16)3873 EMBO Mol Med, 2019, 11(10):e10769
S7934	SR9243	SR9243 is a potent and selective LXR inverse agonist.	Front Immunol, 2021, 12:732102 FEBS Lett, 2016, 590(11):1614-29
S6427	AZ876	AZ876 is a novel high-affinity Liver X Receptor (LXR) agonist with Ki values of 0.007 μM and 0.011 μM for human LXRα and LXRβ respectively.	J Clin Invest, 2019, 129(3):1129-1151
S8689	Abequolixron (RGX-104)	Abequolixron (RGX-104) is a orally bioavailable liver X receptor agonist that modulates innate immunity via transcriptional activation of the ApoE gene.
E7041New	Desmosterol	Desmosterol is the immediate unsaturated precursor of cholesterol and the final biosynthetic intermediate in the Bloch pathway and a key activator of liver X receptors(LXR) while inhibiting SREBP to regulate lipid homeostasis. Its reduction promotes mitochondrial ROS production in macrophages and activates the NLRP3 inflammasome exhibiting potential for research in inflammation, metabolism, and cardiovascular diseases.
E0099	GSK3987	GSK3987 is an agonist of pan LXRα/β with EC50s of 50 nM, 40 nM for LXRα-SRC1 and LXRβ-SRC1, respectively. GSK3987 increases the expression of ABCA1 and SREBP-1c and induces cellular cholesterol efflux and triglyceride accumulation.
E1142	GSK2033	GSK2033 is a LXR antagonist with pIC50s of 7 and 7.4 for LXRα and LXRβ, respectively.	J Exp Med, 2025, 222(3)e20230647 bioRxiv, 2023, 10.1101/2023.05.11.540294
S2630	GW3965 HCl	GW3965 HCl is a potent, selective LXR agonist for hLXRα and hLXRβ with EC50 of 190 and 30 nM in cell-free assays, respectively.	Int J Chron Obstruct Pulmon Dis, 2025, 20:411-423 Sci Rep, 2024, 14(1):30786 Regen Ther, 2024, 25:229-237
S7076	T0901317	T0901317 is a potent and selective agonist for both LXR and FXR, with EC50 of ~50 nM and 5 μM, respectively. T0901317 is a dual inverse agonist of RORα and RORγ with Ki of 132 nM and 51 nM, respectively. T0901317 significantly suppresses cell proliferation and induces apoptosis.	J Exp Med, 2025, 222(3)e20230647 Exp Ther Med, 2025, 29(3):46 J Anim Sci Biotechnol, 2024, 15(1):124
S8390	LXR-623	LXR-623 is a novel liver X-receptor(LXR) agonist with IC50 values of 179 nM and 24 nM for LXR-α and LXR-β, respectively. It is orally bioavailable and readily passes the blood-brain barrier.	Acta Neuropathol Commun, 2022, 10(1):40 Cancers (Basel), 2022, 14(16)3873 EMBO Mol Med, 2019, 11(10):e10769
S7934	SR9243	SR9243 is a potent and selective LXR inverse agonist.	Front Immunol, 2021, 12:732102 FEBS Lett, 2016, 590(11):1614-29
S6427	AZ876	AZ876 is a novel high-affinity Liver X Receptor (LXR) agonist with Ki values of 0.007 μM and 0.011 μM for human LXRα and LXRβ respectively.	J Clin Invest, 2019, 129(3):1129-1151
S8689	Abequolixron (RGX-104)	Abequolixron (RGX-104) is a orally bioavailable liver X receptor agonist that modulates innate immunity via transcriptional activation of the ApoE gene.
E0099	GSK3987	GSK3987 is an agonist of pan LXRα/β with EC50s of 50 nM, 40 nM for LXRα-SRC1 and LXRβ-SRC1, respectively. GSK3987 increases the expression of ABCA1 and SREBP-1c and induces cellular cholesterol efflux and triglyceride accumulation.
E7041New	Desmosterol	Desmosterol is the immediate unsaturated precursor of cholesterol and the final biosynthetic intermediate in the Bloch pathway and a key activator of liver X receptors(LXR) while inhibiting SREBP to regulate lipid homeostasis. Its reduction promotes mitochondrial ROS production in macrophages and activates the NLRP3 inflammasome exhibiting potential for research in inflammation, metabolism, and cardiovascular diseases.
E1142	GSK2033	GSK2033 is a LXR antagonist with pIC50s of 7 and 7.4 for LXRα and LXRβ, respectively.	J Exp Med, 2025, 222(3)e20230647 bioRxiv, 2023, 10.1101/2023.05.11.540294
S2630	GW3965 HCl	GW3965 HCl is a potent, selective LXR agonist for hLXRα and hLXRβ with EC50 of 190 and 30 nM in cell-free assays, respectively.	Int J Chron Obstruct Pulmon Dis, 2025, 20:411-423 Sci Rep, 2024, 14(1):30786 Regen Ther, 2024, 25:229-237
S7076	T0901317	T0901317 is a potent and selective agonist for both LXR and FXR, with EC50 of ~50 nM and 5 μM, respectively. T0901317 is a dual inverse agonist of RORα and RORγ with Ki of 132 nM and 51 nM, respectively. T0901317 significantly suppresses cell proliferation and induces apoptosis.	J Exp Med, 2025, 222(3)e20230647 Exp Ther Med, 2025, 29(3):46 J Anim Sci Biotechnol, 2024, 15(1):124
S8390	LXR-623	LXR-623 is a novel liver X-receptor(LXR) agonist with IC50 values of 179 nM and 24 nM for LXR-α and LXR-β, respectively. It is orally bioavailable and readily passes the blood-brain barrier.	Acta Neuropathol Commun, 2022, 10(1):40 Cancers (Basel), 2022, 14(16)3873 EMBO Mol Med, 2019, 11(10):e10769
S7934	SR9243	SR9243 is a potent and selective LXR inverse agonist.	Front Immunol, 2021, 12:732102 FEBS Lett, 2016, 590(11):1614-29
S6427	AZ876	AZ876 is a novel high-affinity Liver X Receptor (LXR) agonist with Ki values of 0.007 μM and 0.011 μM for human LXRα and LXRβ respectively.	J Clin Invest, 2019, 129(3):1129-1151
S8689	Abequolixron (RGX-104)	Abequolixron (RGX-104) is a orally bioavailable liver X receptor agonist that modulates innate immunity via transcriptional activation of the ApoE gene.
E0099	GSK3987	GSK3987 is an agonist of pan LXRα/β with EC50s of 50 nM, 40 nM for LXRα-SRC1 and LXRβ-SRC1, respectively. GSK3987 increases the expression of ABCA1 and SREBP-1c and induces cellular cholesterol efflux and triglyceride accumulation.
E7041New	Desmosterol	Desmosterol is the immediate unsaturated precursor of cholesterol and the final biosynthetic intermediate in the Bloch pathway and a key activator of liver X receptors(LXR) while inhibiting SREBP to regulate lipid homeostasis. Its reduction promotes mitochondrial ROS production in macrophages and activates the NLRP3 inflammasome exhibiting potential for research in inflammation, metabolism, and cardiovascular diseases.